Transaction · 0001470831-26-000883

Cohlhepp Ryan

Cohlhepp Ryan, PRES, COO, IC, reported an open-market or private sale at Bicara Therapeutics Inc. involving 14058.000000 shares for an estimated $320052.86. Reported holdings after the transaction were 185083.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, COO, IC
BCAXBicara Therapeutics Inc.
Trade date
Sep 08, 2026
Filing date
Sep 10, 2026
View on SEC Insider profile
Disclosed value-$320kShares × reported price
Shares traded14.0k$22.77 per share
Holdings after185kDirect
% of reported position traded7.06%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 199,141 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

BCAX price since this filing

Daily closing prices, with the filing date and available return windows
BCAX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +13.1%1w ago +0.0%1d ago +0.0%
Returns since7d -8.9%30d -29.5%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001470831-26-000883
Common Stock
Transaction date
Sep 08, 2026
Filed Sep 10, 2026, 08:23 PM · 2d delay
Shares
14,058 sh
$22.77 per share
Estimated value
-$320k
Computed from shares × price
Holdings after
185,083 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, COO & Interim CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

  2. F2

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide…

  3. F3

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.26 to $23.58, inclusive. The Reporting Person undertakes to provide…

  4. F4

    The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.

Original filing · 0001470831-26-000883
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

BCAX